Introduction
The vascular endothelium plays a central role in the regulation of vascular homeostasis. Alterations in endothelial function have been linked to a variety of inflammatory diseases, including atherosclerosis and diabetes mellitus. 1 Proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-␣), induce endothelial dysfunction by causing an increase in the expression of cell-surface adhesion molecules, such as vascular cell adhesion molecule (VCAM)-1. These changes facilitate the adhesion of circulating blood cells, including neutrophils, leukocytes, and monocytes, to activated endothelial cells, ultimately leading to endothelial dysfunction. 2 Monocyte rolling and adhesion to vascular endothelial cells are initial steps in the development of vascular inflammation. 3 Among the adhesion molecules, VCAM-1 is a key molecule in the recruitment of leukocytes to endothelial cells. Upregulated VCAM-1 expression in endothelial cells is associated with several cardiovascular diseases that involve vascular inflammation. Nuclear factor (NF)-B signaling also plays a pivotal role in vascular inflammation. 4 Ulmus davidiana var. japonica Rehder (Urticales: Ulmaceae) (UD) has traditionally been used for anticancer and antiinflammatory therapy in Asia. 5, 6 Several compounds have been extracted from the stem and root barks of UD, and their functions have been investigated. [7] [8] [9] In previous reports, an extract of UD (UDE) was found to attenuate ovalbumin-induced airway inflammation by increasing hemooxygenase-1 expression, and methanol extracts of UD showed an antiangiogenic effect. 10, 11 Recently, UDE was reported to induce vasorelaxation in an endotheliumdependent manner in rat aorta, suggesting that the vascular endothelium is the target tissue of UDE and that it has a protective effect against endothelial dysfunction. 12 However, the effect of UDE on monocyte adhesion to the endothelial cells remains unclear. This study aimed to examine the protective effect of UDE on TNF-␣-induced monocyte adhesion and elucidate its underlying mechanism.
2.
Materials and methods
Materials
The human monocyte cell line U937 and the human embryonic kidney cell line [human embryonic kidney epithelial 293T (HEK 293T)] were obtained from the American Type Culture Collection (Rockville, MD, USA), and human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (Walkersville, MD, USA). Dulbecco's modified Eagle's medium, fetal bovine serum, and antibiotics were purchased from Gibco (Grand Island, NY, USA), and an endothelial growth medium (EGM-2) SingleQuot kit was purchased from Lonza. Human TNF-␣ was purchased from Sigma-Aldrich (St. Louis, MO, USA). Dichlorofluorescein diacetate (H 2 DCFDA) and 2 ,7 -bis-(2-carboxyethyl)-5-(and-6)-carboxy-fluorescein acetoxymethyl ester probes were purchased from Molecular Probes (Eugene, OR, USA). Antibodies against VCAM-1, NF-B p65, IB␣, poly (ADP-ribose) polymerase (PARP), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and ␤-actin antibody was purchased from Sigma-Aldrich.
Cell cultures and treatment with UD ethanol extracts
HUVECs were cultured in an endothelial growth medium (EGM-2), and the cells were used for up to six passages, according to the manufacturer's instructions. U937 and HEK 293T cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum and antibiotics at the manufacturer's recommended concentration. Each cell line was incubated in an atmosphere of 95% air and 5% CO 2 at 37 • C. Ethanol extract of UD was prepared as described previously. 12 The freeze-dried UDE was thoroughly dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1 mg/mL prior to use in experiments. HUVECs at 80-90% confluence were treated with various concentrations of UDE (1-30 g/mL). As a vehicle-negative control, HUVECs were incubated in a culture medium containing DMSO (0.1%, v/v). Then HUVECs were stimulated with 15 ng/mL of TNF-␣.
Cell viability measurement using bioluminescent assay
The effect of UDE on the viability of HUVECs was analyzed using a RealTime-Glo MT luminescent kit (Promega, Madison, WI, USA) in an opaque-walled assay plate, according to the manufacturer's instructions. The permeable viability prosubstrate in live cells is reduced to a luciferase substrate by metabolically active cells, while dead cells neither reduce the substrate nor produce a signal. The reduced substrate diffuses from cells into the surrounding culture medium and is then rapidly used by luciferase to produce a luminescent signal, which shows a correlation with viability. HUVECs in the assay-plate were treated with various concentrations of UDE (1-30 g/mL) for 24 hours. To continuously monitor the viability of the treated HUVECs in real time, the prosubstrate and luciferase were added at the same time as the UDE. Luminescence intensity at the desired time points was measured using a luminometer (Thermo Scientific, Rockford, IL, USA). Each sample was analyzed at least in triplicate.
Measurement of reactive oxygen species
The intracellular reactive oxygen species (ROS) level was measured using a membrane-permeant H 2 DCFDA fluorogenic probe, as described previously. 13 Briefly, 1 × 10 5 cells were seeded in a 12-well plate and allowed to attach overnight. The cells were pretreated with various concentrations of UDE (1-30 g/mL) for 1 hour and then stimulated with 15 ng/mL of TNF-␣ for 3 hours. Subsequently, the cells were stained with 5 M H 2 DCFDA for 30 minutes at 37 • C. The cells were collected, and fluorescence was measured using a Fluoroskan Ascent microplate reader (Thermo Scientific) at wavelengths of 485 nm for excitation and 530 nm for emission.
Monocyte-endothelial cell adhesion assay
The monocyte-endothelial cell adhesion assay was performed as previously described. 14 
Immunoblotting
Cells were harvested and the cell lysates were prepared as previously described. 15 The total protein concentration was measured using the Bradford assay. For some experiments, nuclear and cytosolic fractions were prepared using a cell fractionation kit (Abcam, Cambridge, UK). 13 The purity of the nuclear fraction was confirmed using an antibody against the nuclear marker PARP. The same concentration of protein was resolved by sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride membrane. Immunoblotting was performed using anti-VCAM-1, NF-B p65, IB␣, PARP, GAPDH, and ␤-actin antibodies. The intensity of bands was quantified in an EpiChem 3 Darkroom using LabWorks software (UVP, Upland, CA, USA), followed by normalization of band densities to ␤-actin.
Immunocytochemistry
Immunocytochemical localization of the NF-B p65 subunit was performed as previously described. 16 HUVECs were cultured on glass coverslips in 12-well plates and treated with TNF-␣ after pretreatment with 10 g/mL UDE. After washing with phosphate-buffered saline (PBS), cells were fixed with 4% (w/v) paraformaldehyde and permeabilized with 0.1% (v/v) Triton X-100. After blocking for 1 hour with PBS containing 2% (w/v) bovine serum albumin and 5% (v/v) horse serum, cells were incubated with NF-B p65 antibody (1:500) overnight at 4 • C and then labeled with Alexa Fluor 488-conjugated secondary antibody (1:500) for 1 hour in the dark at room temperature. Images were obtained by fluorescence microscopy.
Luciferase assay using in vitro imaging
For this experiment, HEK 293T cells were cotransfected with pGL3.1 VCAM-1 promoter firefly luciferase reporter plasmid and pcDNA4, and selected by 0.4 mg/mL Zeocin in culture for 4 weeks. To establish a clonal population stably expressing a homogenous level of luciferase, a couple of different clones were isolated to represent different intensities of luciferase activity. Following expansion, each clone was analyzed using a Lumina XRMS in vitro imaging system (PerkinElmer Inc., Waltham, MA, USA) to ensure luciferase activity. The HEK 293T/VCAM-1-luc cells were plated in an opaque-walled 96-well plate (4 × 10 4 cells/well) and allowed to attach overnight. The cells were incubated with UDE in a concentrationdependent manner for 1 hour, followed by TNF-␣ stimulation and then further incubation for 6 hours. Subsequently, the cells were treated with luciferin for 30 minutes at 37 • C, and the resulting biophotonic reaction was measured using the Lumina XRMS imaging system and analyzed using Living Image Software 4.4 (PerkinElmer Inc.).
Statistical analysis
The data are expressed as the mean ± standard error of the mean (SEM). Statistical significance was analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's or Bonferroni's multiple comparison tests using Prism 5 software (GraphPad, La Jolla, CA, USA), and p < 0.05 was considered significant.
Results

Effect of UDE on the viability of HUVECs
To investigate the potential cytotoxic effects of UDE, the effect of UDE treatment on the viability of HUVECs was examined using a bioluminescent assay. HUVEC viability was consistently high at the desired treatment concentrations of UDE (1-30 g/mL), but decreased viability was detected at 50 g/mL of UDE (Fig. 1) . HUVECs demonstrated more than 95% viability at 30 g/mL UDE, indicating that it did not cause nonspecific cytotoxicity at the highest concentration used for treatments (Fig. 1) . The treated HUVECs were also observed under phasecontrast microscopy, and no effects on HUVEC morphology could be observed after UDE treatment even at 30 g/mL (data not shown). Collectively, it was determined that UDE treatment did not affect HUVEC viability adversely, and concentrations of < 30 g/mL can be considered safe.
Effect of UDE on monocyte adhesion in TNF-˛-stimulated HUVECs
Recently, much evidence for the anti-inflammatory biological activity of natural agents has been reported in vascular inflammation models. The anti-inflammatory activity of these agents has generally been reported to be mediated by the inhibition of ROS generation, expression of adhesion molecules, and NF-B activity, leading to reduced leukocyte adherence in the process of leukocyte trafficking. We determined the effect of UDE treatment on monocyte adhesion to endothelial cells. HUVECs were pretreated with the UDE (3-30 g/mL) and then incubated with TNF-␣ for 18 hours. Adhesion of fluorescently labeled monocytes to stimulated endothelial cells was observed under fluorescent microscopy ( Fig. 2A) . TNF-␣-induced monocyte adhesion was inhibited by UDE treatment in a concentration-dependent manner. Exposure to 30 g/mL UDE resulted in a 21% decrease in monocyte adhesion compared with that in the DMSO-treated control cells (Fig. 2B) . The decrease in fluorescence intensity induced by UDE treatment was found to occur in a concentrationdependent manner. These results indicated that UDE may inhibit monocyte adherence to the endothelial cell surface.
3.3.
Effects of UDE on the adhesion molecule VCAM-1
During the process of monocyte trafficking, monocyte adherence is largely controlled by the regulation of surfaceexpressed, cell adhesion molecules in response to secreted chemokines. To examine whether UDE treatment modified monocyte adhesion by causing an altered expression of cellsurface adhesion molecules, we determined the expression level of the adhesion molecule VCAM-1 on the surface of TNF-␣-stimulated HUVECs. Exposure of HUVECs to TNF-␣ induced a significant upregulation of VCAM-1 expression (Fig. 3A,  3B ). Treatment with UDE caused a significant inhibition of TNF-␣-induced VCAM-1 expression in a concentrationdependent manner. At the maximum tested treatment concentration of UDE (30 g/mL), the TNF-␣-induced increase in VCAM-1 expression was decreased by 36% (Fig. 3A, 3B) . Additionally, we analyzed the transcriptional activity of VCAM-1 using a luciferase reporter assay in HEK 293T/VCAM-1-luc cells, which were stably transfected with the human VCAM-1 promoter gene, and the results are shown in Fig. 3C  and 3D . Indeed, an increase in the transcriptional activity of VCAM-1 was observed in TNF-␣-stimulated HEK293T/VCAM-1-luc cells, which exhibited a bright biophotonic emission. Representative image and relative luciferase activities for VCAM-1 in TNF-␣-stimulated HEK293T/VCAM-1-luc cells, after treatment with UDE, are shown in Fig. 3C and 3D . A significant decrease in VCAM-1 transcriptional activity was observed in UDE-treated TNF-␣-stimulated HEK 293T/VCAM-1-luc cells. Similar to the results for VCAM-1 expression (Fig. 3A) , UDE treatment was also found to elicit a downregulation of VCAM-1 transcriptional activity. Owing to treatment with UDE at 30 g/mL, TNF-␣-induced VCAM-1 transcriptional activity was inhibited by 17.4% (Fig. 3D). 
Fig. 3 -UDE treatment resulted in altered expression levels of the adhesion molecule VCAM-1 in TNF-␣-stimulated HUVECs. (A) Immunoblotting for adhesion molecule VCAM-1 using lysates from TNF-␣-stimulated HUVECs treated with DMSO or UDE at the indicated concentrations (0-30 g/mL). Blots were stripped and reprobed with anti-␤-actin antibody to correct for differences in protein loading. (B) The expression of VCAM-1 relative to that of ␤-actin was calculated for each treatment group based on the densitometric scanning data of each band. Similar results were observed in replicate experiments (n = 3). (C and D) The transcriptional activity of VCAM-1 in TNF-␣-stimulated HEK 293T cells was determined by a luciferase reporter gene assay. HEK 293T/VCAM-1-luc cells (4 ×
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Effect of UDE on ROS generation in TNF-˛-stimulated HUVECs
Next, intracellular ROS generation in TNF-␣-stimulated HUVECs after UDE treatment was measured using the H 2 DCFDA fluorescent probe. As shown in Fig. 4 , TNF-␣ stimulation induced increased intracellular ROS generation compared with that measured in DMSO-treated control cells. However, treatment with UDE led to a downregulation of ROS generation in a concentration-dependent manner, compared with that in HUVECs treated with TNF-␣ alone. In particular, treatment with 30 g/mL UDE almost completely abrogated TNF-␣-induced ROS generation, suggesting that UDE could effectively attenuate endothelial dysfunction by inhibiting TNF-␣-induced ROS generation.
Effect of UDE on NF-ÄB localization and signaling in TNF-˛-treated HUVECs
The transcription factor NF-B, which acts as a central mediator of inflammatory responses, has been known to regulate the expression of adhesion proteins in TNF-␣-induced vascular inflammation. 17, 18 The anti-inflammatory effect of many natural products results from the inhibition of NF-B activity in various cell types, which explains our results on UDE-mediated downregulation of the VCAM-1 proteins in TNF-␣-stimulated HUVECs (Fig. 3A) . To confirm the inhibition of NF-B in TNF-␣-stimulated HUVECs under our experimental conditions, we determined the effect of UDE treatment on nuclear translocation of NF-B p65, which is necessary for its activation. Initially, we performed immunoblotting for NF-B p65 using nuclear and cytosol fractions prepared from TNF-␣-stimulated HUVECs treated with different concentrations of UDE for 1 hour. As shown in Fig. 5A , UDE treatment caused a marked decrease in the nuclear level of NF-B p65 that was evident as low as 3 g/mL UDE after treatment. The UDE-mediated inhibition was also evident from a reciprocal increase of cytoplasmic localization of NF-B p65 at the same concentration (Fig. 5A) . The membranes were stripped and reprobed with anti-PARP and/or GAPDH antibodies to ensure equal protein loading, as well as to rule out crosscontamination of nuclear and cytoplasmic fractions (Fig. 5A) . Additionally, IB degradation, which is a critical step for NF-B activation leading to nuclear translocation, was obviously prevented even with 3 g/mL UDE treatment (Fig. 5B) .
Next, we performed immunocytochemistry to further examine the effect of UDE treatment on nuclear/cytoplasmic localization of NF-B p65. As shown in Fig. 5C , the NF-B p65 (green fluorescence) immunostaining was evident in both the nucleus (red fluorescence) and the cytoplasm of nonstimulated HUVECs compared with the mainly nuclear localization of NF-B p65 in TNF-␣-stimulated cells. Similar to the result of Fig. 5A , UDE treatment significantly attenuated TNF-␣-induced nuclear translocation of NF-B p65 and restricted it to the cytoplasm, indicating inhibition of its nuclear translocation and its activity (Fig. 5C ).
Discussion
Here, we demonstrated that UDE treatment inhibits TNF-␣-induced monocyte adhesion to endothelial cells, and that its antiadhesive activity might be due to the inhibition of VCAM-1 protein and/or transcriptional activity for VCAM-1.
In the present study, we showed the effect of UDE on endothelial cell viability. UDE at a concentration of less than 30 g/mL exerted antiadhesive activity without affecting endothelial cell viability. However, a high dose of UDE (more than 50 g/mL) reduced cell viability, suggesting nonspecific cell toxicity at such high doses. UD is also used as a traditional medicine for its antitumor activities. In previous reports, UDE (more than 50 g/mL) exerted antitumor activity. 19 Therefore, pharmacological use of high doses of UDE may be possible, but requires further study and careful consideration of the benefits and risks. Our cell viability results could serve as fundamental data for the development of antitumor drugs lacking nonspecific cell toxicity.
Adhesion of circulating monocytes to the arterial endothelium is the initial event in the development of chronic inflammatory diseases such as atherosclerosis, and it is mainly regulated by a combination of cell-surface adhesion molecules. VCAM-1 is an adhesion protein that appears on the surface of endothelial cells after exposure to inflammatory cytokines. VCAM-1 is a ligand for the integrin receptor very late activation antigen (VLA)-4. 20 Binding of VCAM-1 to VLA-4 is a key regulator of monocyte adhesion in endothelial cells. The area of early atherosclerotic lesions in the aorta was reduced significantly in VCAM-1 knockout mice, indicating that VCAM-1 plays a dominant role in the initiation of atherosclerosis. 21 In the present study, UDE treatment inhibited TNF-␣-induced monocyte adhesion in endothelial cells. Additionally, western blot and promoter assays revealed that the antiadhesive activity of UDE is mainly due to the inhibition of TNF-␣-induced VCAM-1 protein expression and its transcriptional activity. Especially, the effect of UDE on the transcriptional activity of VCAM-1 was evaluated in stable cell lines to avoid variable protein expressions among individual cells that can occur with transient transfection. We generated stable HEK293T cell lines containing the region from -1716 to +119 of the human VCAM-1 promoter into pGL3.1 plasmids (kindly donated by Y.G. Kwon, Yonsei University). 22 Then, this luciferase activity was analyzed using a high-sensitivity in vitro imaging system to visualize the luciferase signal. A significant decrease in VCAM-1 transcriptional activity was confirmed in UDE-treated TNF-␣-stimulated HEK 293T/VCAM-1-luc cells.
ROS are created by a variety of cellular processes as part of cellular signaling events. 23 Proinflammatory cytokines, such as TNF-␣, increase ROS generation in inflammatory diseases. 24, 25 In particular, Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and mitochondrial ROS were shown to be involved in TNF-␣-induced VCAM-1 expression and monocyte adhesion in endothelial cells. 26 In the present study, our data showed that treatment of cells with 30 g/mL UDE almost completely abrogated TNF-␣-induced ROS generation, suggesting that UDE could effectively attenuate endothelial dysfunction by inhibiting TNF-␣-induced ROS generation.
NF-B is regulated by the intracellular redox status. 23 It has been reported that oxidants that enhance ROS generation also induce NF-B activation. Indeed, excess generation of ROS is involved in the majority of signaling pathways that cause IB degradation and NF-B nuclear accumulation. Transcriptional activation of NF-B increases the expression of adhesion molecules, such as VCAM-1, subsequently leading to monocyte adhesion and transmigration across the endothelial barrier into the vessel wall. 17, 18 In this study, we clearly demonstrated that UDE attenuates TNF-␣-induced NF-B p65 nuclear translocation and IB␣ degradation. Therefore, given these correlations between NF-B and endothelial dysfunction, we can speculate that UDE suppresses NF-B signaling.
Several kinds of candidate natural compounds can be involved in antiadhesive activity. Phytochemical components of UD that have been demonstrated to have cytoprotective effects in a purified form include epigallocatechin-3-gallate, catechin, triterpene ester, and sesquiterpene O-naphthoquinones. [27] [28] [29] [30] Based on our knowledge, UDE has been shown to have antiadhesive and vasorelaxant activities.
Therefore, UDE could be used as a part of a drug formula to inhibit chronic vascular inflammation, enhance blood flow, and/or facilitate blood circulation.
Conclusion
Taken together, we demonstrated that UDE inhibits TNF-␣-induced monocyte adhesion in endothelial cells and that its antiadhesive activity was at least partly due to the inhibition of VCAM-1 expression, which is regulated by ROS and NF-B signaling. Our results provide new insight into the cellular mechanisms underlying the protective activity of UDE against endothelial dysfunction in chronic vascular inflammatory diseases.
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